CERULETIDE, A CHOLECYSTOKININ-RELATED PEPTIDE, ATTENUATES HALOPERIDOL-INDUCED INCREASE IN DOPAMINE RELEASE FROM THE RAT STRIATUM - AN INVIVO MICRODIALYSIS STUDY

被引:13
作者
KIHARA, T
IKEDA, M
MATSUSHITA, A
机构
[1] Shionogi Research Laboratories, Fukushima-ku, Osaka, Shionogi
关键词
Ceruletide; Depolarization inactivation; Dopamine release; Haloperidol; In vivo microdialysis; Rat; Striatum;
D O I
10.1016/0006-8993(90)90058-J
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The effects of ceruletide diethylamine (CLT), a cholecystokinin (CCK)-related peptide, on the spontaneous and haloperidol (HPD)-induced release of striatal dopamine (DA) were investigated with the in vivo microdialysis method. The striatum was perfused with Ringer solution containing different concentrations of K+. (1) When the dialysis tube was perfused with 4 mM K+-containing Ringer solution, CLT exerted no influence on the spontaneous and HPD-induced release of DA. (2) Increasing the K+ concentration in the perfusate from 4 to 15 mM failed to change the spontaneous and HPD-induced DA release. In this perfusion condition, the HPD-induced increase in DA release was significantly attenuated by CLT. (3) Perfusion of the striatum with the 20 mM K+ significantly reduced both the spontaneous and HPD-induced output of DA. (4) Even under the condition of perfusing the dialysis tube with the 4 mM K+, CLT significantly decreased the HPD-stimulated DA release in rats given HPD alone for the first 7 days and with CLT for the last 3 days. (5) Sixty consecutive daily administrations of HPD alone markedly reduced HPD-induced DA release from the striatum perfused with the Ringer solution containing 4 mM K+. From these results, we suggest that CLT, under the appropriate depolarization, can facilitate or induce depolarization inactivation of the A9 DA cells and/or nigrostriatal DA terminals, and consequently, produce significant inhibition of HPD-induced DA release from the rat striatum. © 1990.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 34 条
[1]  
ALBUS M, 1984, ARCH GEN PSYCHIAT, V41, P528
[2]   CHOLECYSTOKININ ATTENUATES BASAL AND DRUG-INDUCED INCREASES OF LIMBIC AND STRIATAL DOPAMINE RELEASE [J].
ALTAR, CA ;
BOYAR, WC ;
OEI, E ;
WOOD, PL .
BRAIN RESEARCH, 1988, 460 (01) :76-82
[3]  
[Anonymous], 1979, STEREOTAXIC ATLAS RA
[4]   REVERSAL BY CHOLECYSTOKININ OF APOMORPHINE-INDUCED INHIBITION OF DOPAMINE RELEASE IN THE NUCLEUS-ACCUMBENS OF THE RAT [J].
BLAHA, CD ;
PHILLIPS, AG ;
LANE, RF .
REGULATORY PEPTIDES, 1987, 17 (06) :301-310
[5]   ACUTE AND CHRONIC HALOPERIDOL TREATMENT - COMPARISON OF EFFECTS ON NIGRAL DOPAMINERGIC CELL ACTIVITY [J].
BUNNEY, BS ;
GRACE, AA .
LIFE SCIENCES, 1978, 23 (16) :1715-1727
[6]  
CHIODO LA, 1987, J NEUROSCI, V7, P629
[7]   DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN PATHOPHYSIOLOGY OF TARDIVE-DYSKINESIA [J].
GERLACH, J ;
REISBY, N ;
RANDRUP, A .
PSYCHOPHARMACOLOGIA, 1974, 34 (01) :21-35
[8]  
GRACE AA, 1986, J PHARMACOL EXP THER, V238, P1092
[9]   CERULETIDE SUPPRESSES ENDOGENOUS DOPAMINE RELEASE VIA VAGAL AFFERENT SYSTEM, STUDIED BY INVIVO INTRACEREBRAL DIALYSIS [J].
HAMAMURA, T ;
KAZAHAYA, Y ;
OTSUKI, S .
BRAIN RESEARCH, 1989, 483 (01) :78-83
[10]  
HIRAYAMA K, 1988, NEUROPEPTIDES BASIS, P374